The conversion of native peptides and proteins into amyloid aggregates is a hallmark of over
50 human disorders, including Alzheimer's and Parkinson's diseases. Increasing evidence …

Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Abstract α-Synuclein (α-Syn) aggregation and amyloid formation is directly linked with
Parkinson's disease pathogenesis. However, the early events involved in this process …

Liquid–liquid phase separation (LLPS) is an emerging phenomenon in cell physiology and
diseases. The weak multivalent interaction prerequisite for LLPS is believed to be facilitated …

Abstract α-Synuclein (α-Syn) has been extensively studied for its structural and biophysical
properties owing to its pathophysiological role in Parkinson's disease (PD). Lewy bodies …

Aberrant aggregation of the misfolded presynaptic protein, α-Synuclein (α-Syn) into Lewy
body (LB) and Lewy neuritis (LN) is a major pathological hallmark of Parkinson's disease …

In the last two decades, solid-state nuclear magnetic resonance (ssNMR) spectroscopy has
transformed from a spectroscopic technique investigating small molecules and industrial …

Misfolded α-synuclein is a major component of Lewy bodies, which are a hallmark of
Parkinson's disease (PD). A large body of evidence shows that α-synuclein can aggregate …

Abnormal accumulation of aggregated α-synuclein (α-Syn) is seen in a variety of
neurodegenerative diseases, including Parkinson's disease (PD), multiple system atrophy …

Synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple
system atrophy, are triggered by α-synuclein aggregation, triggering progressive …